Philip S. Barie

TL;DR: DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock, and rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death.

TL;DR: A task force of 11 experts in the disciplines related to critical care medicine and infectious diseases concluded that, because fever can have many infectious and noninfectious etiologies, a new fever in a patient in the intensive care unit should trigger a careful clinical assessment rather than automatic orders for laboratory and radiologic tests.

TL;DR: Evidence-based recommendations regarding the use of RBC transfusion in adult trauma and critical care will provide important information to critical care practitioners.

TL;DR: This phase 3 trial compared ceftolozane/tazobactam plus metronidazole vs meropenem for the treatment of complicated intra-abdominal infections with high rates of presumed microbiological eradication of Enterobacteriaceae and Pseudomonas aeruginosa.

TL;DR: This study demonstrated no statistically significant difference between the treatment groups for pancreatic or peripancreatic infection, mortality, or requirement for surgical intervention, and did not support early prophylactic antimicrobial use in patients with severe acute necrotizing pancreatitis.